Your browser doesn't support javascript.
loading
Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.
Vilgelm, Anna E; Pawlikowski, Jeff S; Liu, Yan; Hawkins, Oriana E; Davis, Tyler A; Smith, Jessica; Weller, Kevin P; Horton, Linda W; McClain, Colt M; Ayers, Gregory D; Turner, David C; Essaka, David C; Stewart, Clinton F; Sosman, Jeffrey A; Kelley, Mark C; Ecsedy, Jeffrey A; Johnston, Jeffrey N; Richmond, Ann.
Afiliação
  • Vilgelm AE; Tennessee Valley Healthcare System, Department of Veterans Affairs, Vanderbilt University Medical Center, Nashville, Tennessee. Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Pawlikowski JS; Tennessee Valley Healthcare System, Department of Veterans Affairs, Vanderbilt University Medical Center, Nashville, Tennessee. Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Liu Y; Tennessee Valley Healthcare System, Department of Veterans Affairs, Vanderbilt University Medical Center, Nashville, Tennessee. Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Hawkins OE; Tennessee Valley Healthcare System, Department of Veterans Affairs, Vanderbilt University Medical Center, Nashville, Tennessee. Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Davis TA; Department of Chemistry and Vanderbilt Institute of Chemical Biology, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Smith J; Meharry Medical College, Nashville, Tennessee.
  • Weller KP; Flow Cytometry Shared Resource, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Horton LW; Tennessee Valley Healthcare System, Department of Veterans Affairs, Vanderbilt University Medical Center, Nashville, Tennessee. Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee.
  • McClain CM; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Ayers GD; Division of Cancer Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Turner DC; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Essaka DC; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Stewart CF; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Sosman JA; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Kelley MC; Division of Surgical Oncology, Department of Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Ecsedy JA; Takeda Pharmaceuticals International Co., Cambridge, Massachusetts.
  • Johnston JN; Department of Chemistry and Vanderbilt Institute of Chemical Biology, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Richmond A; Tennessee Valley Healthcare System, Department of Veterans Affairs, Vanderbilt University Medical Center, Nashville, Tennessee. Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee. ann.richmond@vanderbilt.edu.
Cancer Res ; 75(1): 181-93, 2015 Jan 01.
Article em En | MEDLINE | ID: mdl-25398437

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Melanoma Experimental / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogênicas c-mdm2 / Aurora Quinase A / Melanoma Limite: Animals / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Melanoma Experimental / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogênicas c-mdm2 / Aurora Quinase A / Melanoma Limite: Animals / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2015 Tipo de documento: Article